Pyritinol
treatment of SDAT patients: evaluation by psychiatric and neurological
examination, psychometric testing and rCBF measurements.
Knezevic S, Mubrin Z, Risberg J, Vucinic G,
Spilich G, Gubarev
N, Wannenmacher W.
Department of Neurology,
University Hospital Centre, Zagreb, Yugoslavia.
Int Clin Psychopharmacol 1989 Jan;4(1):25-38
ABSTRACT
A group of 26 patients with the diagnosis of
Senile Dementia of Alzheimer type (SDAT) was included by random assignment in
a double-blind, cross-over trial of pyritinol versus placebo. The
patients had a mild to moderate degree of dementia. Psychiatric and
neurological examination, psychometric testing, and measurement of the
regional cerebral blood flow (rCBF) at rest and during mental activation were
used to assess treatment effects. The results of the study showed that pyritinol
was associated with a significant improvement in cognitive performance.
RCBF data showed that treatment with pyritinol normalized the pattern of blood
flow increase during activation and improved the score on the test used for
activation.
